A Multi-Center Study of Riociguat in Patients With Sickle Cell Diseases

Recruiting in Palo Alto (17 mi)

+20 other locations

Overseen byMark Gladwin, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Mark Gladwin

Prior Safety Data

Trial Summary

What is the purpose of this trial?

The proposed study is a Phase 2 multi-center, randomized, double-blind, placebo-controlled, parallel groups study aimed to evaluate the safety, tolerability and the efficacy of riociguat compared with placebo in patients with sickle cell disease (SCD).

Research Team

Mark Gladwin, MD

Principal Investigator

University of Pittsburgh

Eligibility Criteria

Inclusion Criteria

Age ≥ 18 years

Sickling disorder (HbSS, HbSC, HbSbeta-thalassemia, HbSD, HbSO-Arab documented by hemoglobin electrophoresis or HPLC fractionation)

Females of reproductive potential (FRP) must have a negative, pre-treatment pregnancy test. Post-menopausal women (defined as no menses for at least 1 year or post-surgical from bilateral oophorectomy) are not required to undergo a pregnancy test.

See 3 more